Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 14/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.64 |
| ▸ | FLT3 | P36888 | 9/20 | 0.64 |
| ▸ | CSF1R | P07333 | 7/20 | 0.64 |
| ▸ | FLT1 | P17948 | 6/20 | 0.50 |
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | RAF1 | P04049 | 4/20 | 0.47 |
| ▸ | BRAF | P15056 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524223 | 0.93 | FLT4 (0.66) | FLT4PDGFRBFLT3CSF1RFLT1 | |
| SCHEMBL4518518 | 0.92 | FLT4 (0.74) | FLT4PDGFRBFLT3CSF1RFLT1 | |
| SCHEMBL4515155 | 0.90 | FLT4 (0.60) | FLT4PDGFRBFLT3CSF1RFLT1 | |
| SCHEMBL4513490 | 0.89 | FLT4 (0.64) | FLT4PDGFRBFLT3CSF1RFLT1 | |
| SCHEMBL4532811 | 0.88 | FLT4 (0.68) | FLT4PDGFRBFLT3CSF1RFLT1 | |
| SCHEMBL4518132 | 0.88 | FLT4 (0.68) | FLT4PDGFRBFLT3CSF1RFLT1 | |
| SCHEMBL4520506 | 0.86 | PDGFRB (0.71) | FLT4PDGFRBFLT3CSF1RKDR | |
| SCHEMBL4524610 | 0.84 | PDGFRB (0.65) | FLT4PDGFRBFLT3CSF1RKDR | |
| SCHEMBL4513297 | 0.84 | PDGFRB (0.72) | FLT4PDGFRBFLT3CSF1RKDR | |
| SCHEMBL4525249 | 0.84 | PDGFRB (0.64) | FLT4PDGFRBFLT3CSF1RFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | FLT4 13/4885PDGFRB 1287/4885FLT3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.